home / stock / arfxf / arfxf news

ARFXF News and Press, Amorfix Life Sciences Ltd From 04/07/22

Stock Information
Company Name: Amorfix Life Sciences Ltd
Stock Symbol: ARFXF
Market: OTC
Website: promisneurosciences.com
Menu
ARFXF ARFXF Quote ARFXF Short ARFXF News ARFXF Articles ARFXF Message Board
Get ARFXF Alerts

News, Short Squeeze, Breakout and More Instantly...
ARFXF - ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders

TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “ Corporation ”) , is pleased to announce it has mailed the Notice of Notice-and-Access (the “...
ARFXF - ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit

TORONTO, Ontario and CAMBRIDGE, MA , March 24, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the devel...

ARFXF - ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer's Vaccine at the 2022 International AD/PDTM Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

TORONTO, Ontario and CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) --  ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in t...

ARFXF - ProMIS Neurosciences Announces Fiscal Year 2021 Results

TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targetin...
ARFXF - ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PDTM) and Related Neurological Disorders

TORONTO, Ontario and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the dev...

ARFXF - ProMIS Neurosciences' PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer's disease

TORONTO, Ontario and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, announced t...

ARFXF - ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board

TORONTO, Ontario and CAMBRIDGE, Mass. , Feb. 03, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated i...
ARFXF - ProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its Scientific Advisory Board

TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicat...

ARFXF - ProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory Board

TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in...

ARFXF - ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer's Treatment

TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in...
Previous 10 Next 10